Bayzed joins IPO quest as medical rivalry heats up
The cancer treatment specialist is seeking a Hong Kong listing to fund its campaign in the M&A battle for China’s private healthcare market Key Takeaways: Over the past three years, Bayzed…
Recent Articles
RELATED ARTICLES
-
Airdoc Tech enjoys healing properties of medical AI rally
2251.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
- Cash-strapped Mirxes looks for lifeline in blood-based cancer detection
- TCMTech fuses old with the new by mixing AI and Chinese medicine
- IPO pitch puts BrainAurora’s earnings under the microscope
-
Bumper dividend could trigger buyout for Ping An Health
1833.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
